Observational studyBritish journal of haematology2019
Development of a prognostic model for overall survival in multiple myeloma using the Connect
Observational study in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01081028 (Connect® MM- The Multiple Myeloma Disease Registry), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Connect® MM- The Multiple Myeloma Disease Registry
Who cites it
13 citing papers in PubMed.
- Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.Blood cancer journal · 2026Trial
- Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study.Blood advances · 2025Observational
- Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.World journal of surgical oncology · 2024Article
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.American journal of hematology · 2024Article
- Article
- Construction of a Prognosis Model of the Pyroptosis-Related Gene in Multiple Myeloma and Screening of Core Genes.ACS omega · 2022Article
- Machine Learning-Based Overall Survival Prediction of Elderly Patients With Multiple Myeloma From Multicentre Real-Life Data.Frontiers in oncology · 2022Article
- Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities.Frontiers in oncology · 2022Article
- New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data.International journal of laboratory hematology · 2021Article
- Article
- Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.Annals of hematology · 2021Article
- Connect MM Registry as a national reference for United States multiple myeloma patients.Cancer medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.